Norman T Ilowite

List of Publications by Year
in descending order

65 papers	7,802 citations	81900 39 h-index	118850 62 g-index
69 all docs	69 docs citations	69 times ranked	4789 citing authors

#	Article	IF	Citations
1	Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis. New England Journal of Medicine, 2000, 342, 763-769.	27.0	1,125
2	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care and Research, 2011, 63, 465-482.	3.4	658
3	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2016, 68, 566-576.	5.6	427
4	Anakinra as firstâ€line diseaseâ€modifying therapy in systemic juvenile idiopathic arthritis: Report of fortyâ€six patients from an international multicenter series. Arthritis and Rheumatism, 2011, 63, 545-555.	6.7	397
5	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.9	338
6	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. Journal of Rheumatology, 2019, 46, 190-197.	2.0	318
7	The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor Î±-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 56, 965-971.	6.7	294
8	Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis and Rheumatism, 2008, 58, 1496-1504.	6.7	285
9	Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis and Rheumatism, 2012, 64, 2012-2021.	6.7	259
10	Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis and Rheumatism, 2003, 48, 218-226.	6.7	228
11	Gene expression profiling of peripheral blood from patients with untreated newâ€onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis and Rheumatism, 2007, 56, 3793-3804.	6.7	216
12	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis and Rheumatism, 2013, 65, 2499-2512.	6.7	211
13	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis Care and Research, 2013, 65, 1551-1563.	3.4	211
14	Consensus treatment plans for newâ€onset systemic juvenile idiopathic arthritis. Arthritis Care and Research, 2012, 64, 1001-1010.	3.4	172
15	Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 1987-1994.	6.7	166
16	Subtypeâ€specific peripheral blood gene expression profiles in recentâ€onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2009, 60, 2102-2112.	6.7	153
17	HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	7.1	139
18	Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care and Research, 2012, 64, 1175-1185.	3.4	137

#	Article	IF	Citations
19	Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 2570-2579.	5.6	130
20	Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intimaâ€media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis and Rheumatism, 2009, 60, 1496-1507.	6.7	125
21	Current Treatment of Juvenile Rheumatoid Arthritis. Pediatrics, 2002, 109, 109-115.	2.1	124
22	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Annals of the Rheumatic Diseases, 2017, 76, 906-913.	0.9	123
23	Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001â€“2004. Arthritis and Rheumatism, 2007, 57, 1439-1445.	6.7	106
24	Juvenile Idiopathic Arthritis. Pediatric Clinics of North America, 2005, 52, 413-442.	1.8	103
25	Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Arthritis and Rheumatology, 2016, 68, 218-228.	5.6	103
26	Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care and Research, 2012, 64, 546-553.	3.4	101
27	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 2871-2880.	5.6	101
28	The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12Âmonths. Pediatric Rheumatology, 2017, 15, 30.	2.1	80
29	Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. Journal of Rheumatology, 2004, 31, 2507-12.	2.0	71
30	Detection of Active Disease in Juvenile Idiopathic Arthritis: Sensitivity and Specificity of the Physical Examination vs Ultrasound. Journal of Rheumatology, 2011, 38, 2671-2674.	2.0	68
31	Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets. Arthritis and Rheumatism, 2009, 60, 2113-2123.	6.7	66
32	An i2b2-based, generalizable, open source, self-scaling chronic disease registry. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 172-179.	4.4	66
33	Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Annals of the Rheumatic Diseases, 2014, 73, 557-566.	0.9	65
34	Clinically Inactive Disease in a Cohort of Children with New-onset Polyarticular Juvenile Idiopathic Arthritis Treated with Early Aggressive Therapy: Time to Achievement, Total Duration, and Predictors. Journal of Rheumatology, 2014, 41, 1163-1170.	2.0	61
35	Juvenile Idiopathic Arthritis. Rheumatic Disease Clinics of North America, 2007, 33, 441-470.	1.9	57
36	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	3.8	57

#	Article	IF	Citations
37	Effects of longâ€term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis and Rheumatism, 2010, 62, 3259-3264.	6.7	54
38	Measuring process of arthritis care: A proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care and Research, 2011, 63, 10-16.	3.4	53
39	Update on biologics in juvenile idiopathic arthritis. Current Opinion in Rheumatology, 2008, 20, 613-618.	4.3	45
40	IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukinâ€1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1319-1330.	5.6	40
41	Panniculitis and fever in children. Journal of Pediatrics, 1993, 122, 372-378.	1.8	31
42	PHARMACOLOGY AND DRUG THERAPY. , 2011, , 71-126.		26
43	Using Registries to Identify Adverse Events in Rheumatic Diseases. Pediatrics, 2013, 132, e1384-e1394.	2.1	25
44	Panniculitis, infection, and dermatomyositis: case and literature review. Clinical Rheumatology, 2009, 28, 57-63.	2.2	22
45	Canakinumab for the treatment of active systemic juvenile idiopathic arthritis. Expert Review of Clinical Pharmacology, 2016, 9, 1015-1024.	3.1	22
46	Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatric Rheumatology, 2012, 10, 31.	2.1	19
47	Systemic Lupus Erythematosus in Children and Adolescents. Pediatrics in Review, 2006, 27, 323-330.	0.4	17
48	Giant coronary artery aneurysms in juvenile polyarteritis nodosa: a case report. Pediatric Rheumatology, 2012, 10, 1.	2.1	16
49	Panniculitis and lipodystrophy. Current Opinion in Rheumatology, 2002, 14, 566-570.	4.3	13
50	A Dose Schedule for Intraarticular Steroids in Juvenile Arthritis: Table 1.. Journal of Rheumatology, 2012, 39, 374-376.	2.0	10
51	Cranial Nerve Involvement With Juvenile Polyarteritis Nodosa: Clinical Manifestations and Treatment. Pediatrics, 2010, 126, e719-e722.	2.1	9
52	Treatment of rheumatic diseases in children: special considerations. Rheumatic Disease Clinics of North America, 2002, 28, 461-482.	1.9	8
53	Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives. Expert Opinion on Pharmacotherapy, 2013, 14, 975-989.	1.8	8
54	Systemic Juvenile Idiopathic Arthritis: A Review. Pediatric Annals, 2012, 41, .	0.8	6

#	Article	IF	Citations
55	Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor. Clinical Immunology, 2018, 194, 9-18.	3.2	6
56	Chronic Leg Ulceration as the Presenting Feature of Diffuse Systemic Sclerosis in Childhood. Journal of Pediatrics, 2011, 159, 698.	1.8	5
57	Prevalence of Annexin A5 Resistance in Children and Adolescents with Rheumatic Diseases. Journal of Rheumatology, 2012, 39, 382-388.	2.0	4
58	Novel treatment options for juvenile idiopathic arthritis. Expert Review of Clinical Pharmacology, 2015, 8, 559-573.	3.1	4
59	Wasabi nose: an underreported complication of cyclophosphamide infusions. Clinical Rheumatology, 2011, 30, 1003-1005.	2.2	3
60	Vaccination in pediatric rheumatic diseaseâ€"risks and benefits. Nature Reviews Rheumatology, 2012, 8, 188-190.	8.0	3
61	Systemic Lupus Erythematosus in Children and Adolescents. Pediatrics in Review, 2006, 27, 323-330.	0.4	3
62	Ultrasound and Cartilage Thickness in Juvenile Idiopathic Arthritis: New Findings, New Questions. Journal of Rheumatology, 2013, 40, 1466-1468.	2.0	1
63	Reply. Arthritis and Rheumatology, 2015, 67, 858-858.	5.6	1
64	Management of the Connective Tissue Diseases of Childhood. , 2010, , 249-274.		0
65	A167: Variations in Patterns of Care Across Pediatric Rheumatic Diseases in the Childhood Arthritis & Rheumatology Alliance Network Registry. Arthritis and Rheumatology, 2014, 66, S215-S216.	5.6	0